Truist Financial restated their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a report published on Tuesday morning, Benzinga reports. Truist Financial currently has a $20.00 price objective on the biotechnology company’s stock. Several other brokerages have also recently commented on CHRS. HC Wainwright reissued a buy rating and issued a […]
Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 […]
AlphaCentric Advisors LLC raised its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) by 89.1% during the first quarter, HoldingsChannel reports. The firm owned 354,500 shares of the biotechnology company’s stock after purchasing an additional 167,000 shares during the quarter. Coherus BioSciences makes up about 1.7% of AlphaCentric Advisors LLC’s investment portfolio, […]
StockNews.com began coverage on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a research report report published on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Other analysts also recently issued research reports about the stock. Maxim Group reduced their price objective on shares of Coherus BioSciences from $15.00 […]